Cancer Genetics Inc. is engaged in the field of genomic-based cancer diagnostics. The products and services the Company is developing are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. It targets cancers where prognosis information is critical and where predicting treatment outcomes using available techniques is limited. These cancers include hematological, urogenital and HPV-associated cancers. The Company seeks to provide its tests and services to oncologists and pathologists at hospitals, cancer centers and physician offices, as well as to biopharmaceutical companies and clinical research organizations for their clinical trials. The Company’s services are performed at its laboratories located in New Jersey, North Carolina, Shanghai (China), and Hyderabad, India. Its laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State and NABL (India).